And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. We have a rather busy agenda planned. A family gathering is in store and then we plan to check in on the Pharmalot ancestors. We may even catch up on our reading. And what about you? Now that autumn is here, you can find the nearest orchard and pick some apples, or take a long drive in the country. Maybe you could winterize your castle or stock up on sweaters. You could also place bets on the outcome of the latest to-do in Washington, which is quite fascinating, yes? Well, whatever you do, have a grand time. But be safe. Enjoy, and see you next Wednesday, since we will take a break early next week to observe ancient traditions …

The U.S. judge overseeing nationwide opioid litigation rejected a request by several big pharmacy chains and drug distributors to disqualify himself because he appeared to be biased against them and pressed too hard for a costly settlement, Reuters writes. Calling the opioid crisis “one of the greatest tragedies of our time,” U.S. District Judge Dan Polster in Cleveland admitted he had been “very active” in encouraging a settlement, but said he was “confident that no reasonable person can legitimately question my impartiality.”

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy